Massachusetts is currently home to 3352 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
NCT05791201
Recruiting
The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/17/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Type 1 Diabetes
Register for Updates
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
NCT05784246
Recruiting
The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
06/17/2024
Locations: Massachusetts General Hospital for Children, Boston, Massachusetts
Conditions: Ulcerative Colitis
Register for Updates
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
NCT05746559
Recruiting
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
06/17/2024
Locations: Research Site, Boston, Massachusetts
Conditions: Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass
Register for Updates
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
NCT05743881
Recruiting
The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and mRNA-1345, an mRNA vaccine targeting RSV, in participants aged 5 months to <24 months.
Gender:
All
Ages:
Between 5 months and 24 months
Trial Updated:
06/17/2024
Locations: Umass Memorial Medical Center, Worcester, Massachusetts
Conditions: Respiratory Syncytial Virus, Human Metapneumovirus
Register for Updates
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383
Recruiting
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major atherosclerotic cardiovascular disease (ASCVD) event will significantly reduce the risk of 4-Point-Major Adverse Cardiovascular Events (4P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI), n... Read More
Gender:
All
Ages:
Between 40 years and 79 years
Trial Updated:
06/17/2024
Locations: MGH Clinical Trials, Boston, Massachusetts
Conditions: Primary Prevention of Atherosclerotic Cardiovascular Disease
Register for Updates
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
NCT05737706
Recruiting
A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer, Pancreatic Adenocarcinoma
Register for Updates
Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease
NCT05737602
Recruiting
The Relaxation Response Resiliency Program (3RP) has shown efficacy in improving coping and resilience across diverse populations; however, little is known about how it helps individuals manage the challenges of living with a chronic illness. This study proposes to pilot test an adapted version of the 3RP among patients living with VHL.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Von Hippel-Lindau Disease, Genetic Disorder
Register for Updates
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
NCT05734196
Recruiting
The primary purpose of Study INZ701-104 (the ENERGY study) is to assess the safety and tolerability of INZ-701 in infants with ENPP1 Deficiency or with ABCC6 Deficiency.
Gender:
All
Ages:
1 year and below
Trial Updated:
06/17/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy, ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum
Register for Updates
Vertical Soft Tissue Augmentation With CTG vs ADM
NCT05729607
Recruiting
The study aims at comparing two different approaches for vertical soft tissue augmentation at implant sites exhibiting soft tissue dehiscences: autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
06/17/2024
Locations: Harvard School of Dental Medicine, Boston, Massachusetts
Conditions: Implant Complication
Register for Updates
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626
Recruiting
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main quest... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Metastatic Breast Cancer
Register for Updates
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
NCT05675449
Recruiting
The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination with carfilzomib plus dexamethasone. Part 2 has 2 arms. The first will evaluate the safety and tolerability of elranatamab when given in combination with maplirpacept. The second will identify the optim... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Multiple Myeloma
Register for Updates
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
NCT05636176
Recruiting
This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. Participants will get study medicine for once-monthly injections either in a pre-filled syringe to inject the study medicine into a skinfold or a pen-injector to inject the study medicine into flat skin. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have to u... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Pentucket Medical Associates, Haverhill, Massachusetts
Conditions: Heart Failure
Register for Updates